News & Updates
Explore the latest MDS research, advocacy updates, awareness campaigns, and patient resources from the MDS Alliance and its member community.
Enrolment Begins for Elritercept Phase 3 Trial in Lower-Risk MDS Patients
15 September 2026
Takeda’s TAK-226-3001 trial at King’s College Hospital, London, compares elritercept with epoetin alfa for anaemia in adults with lower-risk MDS, aiming to enrol 300 patients over the next five years.
Read article →Recent articles
Research updates, awareness campaigns, and alliance news from across the MDS community.
15 August 2026
£1 Million Grant to Transform MDS Treatment
Professor Shahram Kordasti and Professor Mieke Van Hemelrijck (King’s College London) have been awarded a £1 million MRC grant to lead the international i4MDS Consortium, studying the role of the immune system in MDS.
Read article →
15 July 2026
FDA Approves TREGZI™ – a Game-Changing Cell Therapy for Transplant Patients
The FDA has approved Orca Bio’s TREGZI, a precision-engineered cell therapy shown to double chronic GVHD-free survival at one year for adults with blood cancers, including MDS, after stem cell transplant.
Read article →
15 May 2026
Art Meets Hematology – Seeing Disease Through a New Lens
AIPaSiM’s “Scientific Art in Hematology” exhibition pairs clinical imagery with artistic expression, offering patients and the public a fresh, more human way of understanding hematologic disease.
Read article →
15 April 2026
British Columbia (Canada) Denies Funding for MDS Drug Covered in Every Other Province
British Columbia is facing criticism for refusing to fund Luspatercept, an MDS treatment publicly covered in every other Canadian province, despite its proven impact on patients’ quality of life.
Read article →
15 March 2026
New £1m Clinical Trial Launches to Improve Quality of Life for MDS
Dr Kevin Rouault-Pierre’s team at Barts Cancer Institute has been awarded a £1 million Cancer Research UK grant for a phase II trial testing whether high-dose vitamin B5 can reduce severe anaemia in MDS patients with an SF3B1 mutation.
Read article →Video and education
Conference highlights and short talks from MDS specialists on diagnosis, prognosis, and treatment.
Post-EHA 2026: MDS highlights
Selected presentations from VJHemOnc’s Post-EHA 2026 MDS Highlights meeting. Chair: Dr Amer Zeidan. Moderators: Dr Yasmin Abaza & Dr María Díez Campelo.
Healthcare professional content
EHA 2026
Luspatercept at the maximum-approved dose in transfusion-dependent lower-risk MDS (MAXILUS)
Matteo Della Porta — Humanitas Research Hospital, Milan
View presentation →
EHA 2026
Early versus delayed ESA in non-transfusion-dependent lower-risk MDS (EPO-PRETAR)
Sophie Park — CHU Grenoble Alpes, Grenoble
View presentation →
EHA 2026
Functional TP53 phenotype score in TP53-mutated MDS
Alexander Streuer — Heidelberg University, Mannheim
View presentation →General education
What is MDS and how do we determine prognosis?
Low-Risk MDS: can we prevent progression?
Treatment of high-risk MDS and the indication for stem cell transplant
Stay up to date
Browse the full news archive for advocacy wins, research updates, and alliance announcements, or get in touch with our team.
